Jacobs Levy Equity Management, Inc Neurocrine Biosciences Inc Transaction History

Jacobs Levy Equity Management, Inc

$25.8 Billion
Q4 2024

A detailed history of Jacobs Levy Equity Management, Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 67,189 shares of NBIX stock, worth $7.66 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

67,189

Previous 524,168 87.18%

Holding current value

$7.66 Million

Previous $60.3 Million 84.8%

% of portfolio

0.04%

Previous 0.24%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$111.62 - $139.44 $51 Million - $63.7 Million	-456,979 Reduced 87.18%	67,189 $9.17 Million
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $22.6 Million - $30.2 Million	-196,919 Reduced 27.31%	524,168 $60.3 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $1.08 Million - $1.19 Million	8,289 Added 1.16%	721,087 $99.3 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $5.22 Million - $5.76 Million	-40,067 Reduced 5.32%	712,798 $98.3 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $6.42 Million - $8.03 Million	60,491 Added 8.74%	752,865 $99.2 Million
Q3 2023 Nov 16, 2023	BUY	$94.02 - $117.1 $24.2 Million - $30.1 Million	256,920 Added 59.0%	692,374 $77.9 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $368,684 - $431,854	4,118 Added 0.95%	435,454 $41.1 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $34.6 Million - $45.2 Million	367,229 Added 572.84%	431,336 $43.7 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $5.39 Million - $6.42 Million	50,540 Added 372.52%	64,107 $7.66 Million
Q3 2022 Nov 15, 2022	BUY	$92.03 - $107.81 $1.25 Million - $1.46 Million	13,567 New	13,567 $1.44 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $552,391 - $753,175	-6,308 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $2.19 Million - $2.73 Million	-25,173 Reduced 79.96%	6,308 $605,000
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $379,543 - $533,437	3,947 Added 14.34%	31,481 $3.03 Million
Q2 2020 Aug 17, 2020	SELL	$85.09 - $130.36 $10.5 Million - $16 Million	-122,910 Reduced 81.7%	27,534 $3.36 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $855,352 - $1.3 Million	-11,388 Reduced 7.04%	150,444 $13 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $4.16 Million - $5.68 Million	47,903 Added 42.05%	161,832 $17.4 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $1.71 Million - $2.08 Million	-20,450 Reduced 15.22%	113,929 $10.3 Million
Q2 2019 Aug 13, 2019	BUY	$72.24 - $91.27 $3.63 Million - $4.58 Million	50,210 Added 59.65%	134,379 $11.3 Million
Q1 2019 May 14, 2019	BUY	$69.31 - $91.53 $5.83 Million - $7.7 Million	84,169 New	84,169 $7.42 Million

Others Institutions Holding NBIX

# of Institutions

652

Shares Held

96.5M

Call Options Held

282K

Put Options Held

281K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $10.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account

Jacobs Levy Equity Management, Inc Neurocrine Biosciences Inc Transaction History